

Alexis D Leal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2707365/publications.pdf>

Version: 2024-02-01

19
papers

580
citations

933447

10
h-index

888059

17
g-index

19
all docs

19
docs citations

19
times ranked

1229
citing authors

#	ARTICLE	IF	CITATIONS
1	^{<sup>} Non-V600</sup> <i>BRAF</i> Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2624-2630.	1.6	267
2	North Central Cancer Treatment Group/Alliance trial N08CAâ€”the use of glutathione for prevention of paclitaxel/carboplatinâ€”induced peripheral neuropathy: A phase 3 randomized, doubleâ€”blind, placeboâ€”controlled study. <i>Cancer</i> , 2014, 120, 1890-1897.	4.1	70
3	Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. <i>Supportive Care in Cancer</i> , 2014, 22, 1313-1317.	2.2	46
4	Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in The Iowa Women's Health Study cohort. <i>International Journal of Cancer</i> , 2014, 134, 1741-1750.	5.1	42
5	Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 73-81.	2.3	36
6	An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy. <i>Supportive Care in Cancer</i> , 2015, 23, 55-59.	2.2	30
7	BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative disease. <i>Molecular Cytogenetics</i> , 2012, 5, 23.	0.9	16
8	Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors. <i>Leukemia and Lymphoma</i> , 2015, 56, 434-439.	1.3	14
9	Antiemetic prescribing practices using a computerized physician order entry system. <i>Supportive Care in Cancer</i> , 2014, 22, 217-223.	2.2	13
10	Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 294-299.	4.9	13
11	Variability of performance status assessment between patients with hematologic malignancies and their physicians. <i>Leukemia and Lymphoma</i> , 2018, 59, 695-701.	1.3	11
12	Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. <i>British Journal of Surgery</i> , 2021, 108, 976-982.	0.3	8
13	Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 901-916.	4.1	7
14	Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 151-157.	2.5	3
15	New Adjuvant Trial Designs in Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 326-334.	0.5	2
16	Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens. <i>Clinical Breast Cancer</i> , 2018, 18, e513-e520.	2.4	1
17	Neoadjuvant treatment of localized pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 0-0.	1.4	1
18	Special Issues in Young Women with Triple-Negative Breast Cancer. , 2018, , 141-158.		0

#	ARTICLE	IF	CITATIONS
19	Variability Of Performance Status Assessment Between Patients With Hematologic Malignancies and Their Physicians. Blood, 2013, 122, 1703-1703.	1.4	0